• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

    11.04 +0.51 (+4.84%)
    Delayed Quote Updated: 3:35 PM EST, Nov 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 11,612
    Open 10.41
    Bid (Size) 10.21 (200)
    Ask (Size) 12.98 (100)
    Prev. Close 10.53
    Today's Range 10.41 - 11.48
    52wk Range 8.480 - 16.93
    Shares Outstanding 34,422,063
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy
    Webcast to highlight advancement of the randomized Phase 2 trial of agenT-797 in acute lung injury, the ARPA-H collaboration to advance deployable cell therapeutics, and new data released at the... 
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
    From MiNK Therapeutics
    Via GlobeNewswire

    Performance

    52-Week Range 34.8% below 52-week high
    11.04
    8.4852W Low 16.9352W High
    1 Week 3.8% below 1-week high
    10.351W Low 11.481W High

    MiNK Therapeutics, Inc. - Common Stock (INKT) traded between $8.48 and $16.93 over the past 52 weeks and last traded at $11.04, 34.8% below its 52-week high. Over the past week it ranged between $10.35 and $11.48.

    Past 12 Months
    +5.8%
    -11.3%
    +3.3%
    -4.8%
    -0.7%
    -17.9%
    1W +$0.61
    1M -$1.40
    3M +$0.35
    6M -$0.56
    YTD -$0.08
    1Y -$2.41

    INKT was -17.9% over the past year, -4.8% over six months, -0.7% year to date, +5.8% in the last week.

    12 Months vs Market
    INKT
    -17.9%
    DIA
    +9.7%
    SPY
    +10.1%
    QQQ
    +7.8%
    IWM
    +13.7%

    Over the past 12 months INKT returned -17.9% versus DIA (Dow) +9.7%, SPY (S&P 500) +10.1%, QQQ (Nasdaq 100) +7.8% and IWM (Russell 2000) +13.7%.

    Volume & Liquidity 0.82× 3-mo avg
    Today 11,612 3-mo avg 14.2K
    1W
    9.9K
    1M
    15.8K
    3M
    14.2K
    6M
    20.6K
    YTD
    103.0K
    1Y
    89.6K

    INKT most recently traded 11,612 shares against a 3-month average daily volume of 14.2K.

    More News

    Read More
    News headline image
    MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
    From MiNK Therapeutics
    Via GlobeNewswire
    MiNK Therapeutics (NASDAQ:INKT) Posts Narrower-Than-Expected Q1 Loss, Advances iNKT Therapy Into Pivotal Testing ↗
    Via Chartmill
    News headline image
    MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    MiNK Therapeutics Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK (INKT) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    MiNK (INKT) Q1 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    MiNK Therapeutics Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
    From MiNK Therapeutics
    Via GlobeNewswire
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
    From MiNK Therapeutics
    Via GlobeNewswire
    News headline image
    MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs
    From MiNK Therapeutics
    Via GlobeNewswire

    Frequently Asked Questions

    Is MiNK Therapeutics, Inc. - Common Stock publicly traded?
    Yes, MiNK Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does MiNK Therapeutics, Inc. - Common Stock trade on?
    MiNK Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for MiNK Therapeutics, Inc. - Common Stock?
    The ticker symbol for MiNK Therapeutics, Inc. - Common Stock is INKT on the Nasdaq Stock Market
    What is the current price of MiNK Therapeutics, Inc. - Common Stock?
    The current price of MiNK Therapeutics, Inc. - Common Stock is 11.04
    When was MiNK Therapeutics, Inc. - Common Stock last traded?
    The last trade of MiNK Therapeutics, Inc. - Common Stock was at 11/02/26 03:35 PM ET
    What is the market capitalization of MiNK Therapeutics, Inc. - Common Stock?
    The market capitalization of MiNK Therapeutics, Inc. - Common Stock is 380.02M
    How many shares of MiNK Therapeutics, Inc. - Common Stock are outstanding?
    MiNK Therapeutics, Inc. - Common Stock has 380M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.